乙型肝炎表面抗原
病毒学
抗体
医学
乙型肝炎病毒
结合
药品
乙型肝炎
免疫学
药理学
病毒
数学分析
数学
作者
Xinya Ye,Xiaohong Chen,Han Liu,Yichao Jiang,Chengyu Yang,Tao Xu,Ziyou Chen,Yalin Wang,Chen Fentian,Xue Liu,Hai Yu,Quan Yuan,Ningshao Xia,Yuanzhi Chen,Wenxin Luo
摘要
Abstract Hepatitis B virus (HBV) infection is a significant global health concern due to elevated immunosuppressive viral antigen levels, the host immune system’s inability to manage HBV, and the liver’s immunosuppressive conditions. While immunotherapies utilizing broadly reactive HBV neutralizing antibodies (nAbs) present potential due to their antiviral capabilities and Fc-dependent vaccinal effects, they necessitate prolonged and frequent dosing to achieve optimal therapeutic outcomes. Toll-like receptor 7/8 (TLR7/8) agonists have been demonstrated promise for the cure of chronic hepatitis B (CHB), but their systemic use often leads to intense side effects. In this study, we introduced immune-stimulating antibody conjugates (ISACs) which consist of TLR7/8 agonists 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-imidazo[4,5-c]quinolin-4-amine (IMDQ) linked to an anti-HBsAg antibody 129G1, and designated as 129G1-IMDQ. Our preliminary study highlights that 129G1-IMDQ can prompt robust and sustained anti-HBsAg specific reactions with short-term administration. This underscores the conjugate’s potential as an effective strategy for HBsAg clearance and seroconversion, offering a fresh perspective for a practical therapeutic approach in the functional cure of CHB. Highlights
科研通智能强力驱动
Strongly Powered by AbleSci AI